Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy.

Abstract

Purpose of review: Myocardial infarction survivors are at a high risk of a recurrent event despite receiving guideline preventive therapy. There is accumulated evidence that persistent atherosclerotic plaque inflammation contributes to this risk. Oxidized low-density lipoprotein (LDL) is widely recognized as a key factor in plaque inflammation and instability; however, no therapies that directly target oxidized LDL are to date available for clinical use. We will here review recent observations indicating that treatment with the anti-oxidized LDL antibody orticumab specifically inhibits plaque inflammation.

Recent findings: The effect of orticumab on coronary inflammation in a randomized, double-blind, placebo-controlled pilot phase 2a trial in subjects with moderate to severe psoriasis is a new and recent finding. Coronary inflammation was assessed by calculation of the fat attenuation index (FAI)-Score in the pericoronary adipose tissue in coronary computed tomography angiograms. After 15 weeks of treatment the mean FAI-Score of the three main coronary arteries was significantly reduced in the orticumab group while no change occurred in the placebo group. The effect of orticumab was most pronounced in those with most inflammation at baseline.

Summary: Treatment with orticumab represents a new and plaque-specific way to reduce arterial inflammation.